Private payers have the most experience with managing risk, but each stakeholder must achieve a perfect balance of risk and reward.
While payers traditionally have relied on a fee-for-service approach to reimbursement, today's healthcare landscape increasingly allows payers and providers to enter into agreements that include shared risk. Private payers have the most experience with managing risk, but each stakeholder must achieve a perfect balance of risk and reward.
The Bundled Payment for Care Improvement Initiative is another way CMS hopes to improve the financing of care. Certain services lend themselves to a bundled model, in which providers operate within a budget to deliver a package of services related to one episode of care, such as knee replacement surgery and rehabilitation, for example. Many hope to advance care effectiveness and efficiency now before the market is flooded with new enrollees in the coming years.
Such risk-management agreements don't come without potential pitfalls for payers and providers. What's more, few provider organizations have previous experience, and best practices are still emerging. Healthcare experts believe that before any group enters into risk sharing agreements, the parties involved need to carefully consider what's at stake and determine in advance how potential problems can be prevented.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Doing More and Saving More with Primary in Home Care
September 1st 2021In this week’s episode of Tuning In to the C-Suite podcast, MHE Associate Editor Briana Contreras interviewed VillageMD’s Senior Medical Director of Village Medical at Home, Dr. Tom Cornwell. Dr. Cornwell discussed the main benefits of primary care at home, which includes the benefit of cost savings for patients, maintaining control of hospital readmissions and others. Dr. Cornwell also noted what has changed in the industry of at-home care and if there has been interest from payers like insurance companies and medicare in the service.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More